<DOC>
	<DOCNO>NCT00834262</DOCNO>
	<brief_summary>This study conduct Asia . The aim observational study evaluate safety profile clinical effectiveness use various pre-mixes Biphasic Insulin Aspart routine clinical practice condition Israel Type 2 Diabetes patient .</brief_summary>
	<brief_title>Observational Study Safety Efficacy Biphasic Insulin Aspart Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Any patient type 2 diabetes HbA1c great 7 % insulin without OAD need intensification treatment either NovoMix® 30 NovoMix® 50 NovoMix® 70 combination , eligible Subjects hypersensitivity biphasic insulin aspart excipients . Particular attention pay drug interaction list within product local label . Women pregnant , breast feeding intention become pregnant within next 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>